Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Raised by Townsquare Capital LLC

Townsquare Capital LLC increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 31.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,054 shares of the pharmaceutical company’s stock after purchasing an additional 3,616 shares during the quarter. Townsquare Capital LLC’s holdings in Vertex Pharmaceuticals were worth $7,001,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Quent Capital LLC lifted its position in shares of Vertex Pharmaceuticals by 33.0% in the 1st quarter. Quent Capital LLC now owns 399 shares of the pharmaceutical company’s stock valued at $167,000 after acquiring an additional 99 shares in the last quarter. Cetera Investment Advisers lifted its holdings in shares of Vertex Pharmaceuticals by 193.4% in the first quarter. Cetera Investment Advisers now owns 50,867 shares of the pharmaceutical company’s stock valued at $21,263,000 after purchasing an additional 33,530 shares in the last quarter. Cetera Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 63.2% in the first quarter. Cetera Advisors LLC now owns 13,912 shares of the pharmaceutical company’s stock worth $5,815,000 after buying an additional 5,390 shares during the period. Railway Pension Investments Ltd raised its position in Vertex Pharmaceuticals by 0.9% during the first quarter. Railway Pension Investments Ltd now owns 99,700 shares of the pharmaceutical company’s stock valued at $41,676,000 after buying an additional 900 shares during the period. Finally, Jackson Wealth Management LLC lifted its stake in Vertex Pharmaceuticals by 1.3% in the 1st quarter. Jackson Wealth Management LLC now owns 3,555 shares of the pharmaceutical company’s stock worth $1,486,000 after acquiring an additional 46 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Canaccord Genuity Group lifted their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research note on Wednesday, November 6th. UBS Group upped their price objective on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Oppenheimer decreased their target price on shares of Vertex Pharmaceuticals from $550.00 to $540.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Finally, Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $504.38.

Vertex Pharmaceuticals Trading Down 0.5 %

Shares of VRTX stock opened at $464.56 on Friday. Vertex Pharmaceuticals Incorporated has a 1 year low of $346.29 and a 1 year high of $519.88. The firm’s fifty day simple moving average is $472.81 and its 200 day simple moving average is $474.22. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the previous year, the firm posted $3.67 EPS. The business’s revenue was up 11.6% compared to the same quarter last year. Analysts expect that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.